Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other financing activities (2018 - 2022)

Puma Biotechnology's Other financing activities history spans 3 years, with the latest figure at $69000.0 for Q4 2022.

  • For Q4 2022, Other financing activities fell 96.39% year-over-year to $69000.0; the TTM value through Sep 2023 reached $69000.0, down 96.74%, while the annual FY2022 figure was $277000.0, 85.5% down from the prior year.
  • Other financing activities reached $69000.0 in Q4 2022 per PBYI's latest filing, up from $53000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.9 million in Q4 2021 to a low of $9000.0 in Q4 2018.
  • Average Other financing activities over 3 years is $439200.0, with a median of $69000.0 recorded in 2022.
  • The largest YoY upside for Other financing activities was 96.39% in 2022 against a maximum downside of 96.39% in 2022.
  • A 3-year view of Other financing activities shows it stood at $9000.0 in 2018, then skyrocketed by 21122.22% to $1.9 million in 2021, then crashed by 96.39% to $69000.0 in 2022.
  • Per Business Quant, the three most recent readings for PBYI's Other financing activities are $69000.0 (Q4 2022), $53000.0 (Q3 2022), and $155000.0 (Q1 2022).